GlassScriptPhysician profile
Paresh R Patel
NPI 1912990326
$870.29
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $256 · 2021: $177 · 2022: $202.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $221.40 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.41 | 2020-2022 | |
| Glaxosmithkline, LLC. | $123.16 | 2019-2022 | |
| Shire North American Group INC | $67.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $62.17 | 2021-2022 | |
| Tris Pharma INC | $58.72 | 2019-2020 | |
| Corium, LLC | $50.01 | 2022 | |
| Pfizer INC. | $37.73 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $31.35 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $24.05 | 2019-2020 | |
| Cranial Technologies, INC | $18.72 | 2020 | |
| Sobi, INC | $16.02 | 2021 | |
| Adlon Therapeutics L.P. | $11.19 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paresh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.